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survival. Then 1000 bootstrap data sets were constructed and
analyzed by stepwise forward selection with a criterion for reten-
tion of variables in the models of P  .1. The 1000 models were
then subjected to analyses of correlated variables to quantify
frequency of occurrence of each cluster of variables. The most
frequently occurring member of a cluster appearing in at least 50%
of the bootstrap analyses was selected for the final multivariable
equation. The 50% rule equally balances false-positive and false-
negative identification of risk factors. For each continuous and
ordinal variable selected by the 50% rule, the scaling that most
frequently was observed in these 1000 models was selected as the
transformation incorporated into the final model.
Tabular results of multivariable analyses include an expression
of frequency of bootstrap occurrences (reliability of identification
of risk factors). Regression coefficients rather than hazard ratios
are presented because of the nonproportional nature of the mul-
tiphase hazard method and because of the transformations of scale
required for continuous and ordinal variables.
Discussion
Dr Robert Ginsberg (Toronto, Ontario, Canada). I would like to
congratulate Dr DeCamp and colleagues on a beautifully presented
study. I have a few comments.
The title of the talk appears to assert that this induction che-
moradiotherapy improves survival. I’m not sure that this has been
proved, because there are no valid data for comparison. Be that as
it may, I have a few questions for Dr DeCamp.
First, having had the experience of being in the SWOG study,
was there any difference in selection of your patients with positive
mediastinal lymph nodes? In other words, did you accept patients
with single-station lymph node disease? If so, how many were
there? Only 105 patients in a 6-year period were entered into this
trial. What happened to the other patients with stage IIIA and IIIB
disease at your institution during this time? How often was there
multistation bulky nodal disease among your patients?
When you compare your data with those of SWOG to conclude
that this accelerated chemoradiation improves survival, I have
some questions. In your induction therapy all patients necessarily
had to be hospitalized for their infusion, and 40% also had to be
hospitalized because of toxicity. This occurred before the opera-
tion in the induction phase and after the operation in the adjuvant
phase. Please comment on that and its comparison with the SWOG
4-week chemoradiation preoperative protocol. When you add up
the figures, your protocol is a 12-week protocol, and many induc-
tion chemoradiation protocols nowadays are 4 to 5 weeks of
induction chemoradiation followed by a 3- to 4-week rest, fol-
lowed by surgery. That’s a 10-week protocol.
Your resectability figures were unchanged, your patient com-
pliance figures were unchanged, and your downstaging was un-
changed relative to the SWOG trial—a very simple protocol, and
the time of treatment, even though it was “accelerated hyperfrac-
tionation” of the radiotherapy, was identical to SWOG at 12
weeks.
When you say that you’ve improved survival, what’s the cer-
tainty factor? It’s a decade later, and certainly all of us have had
patient selection changes in our induction therapy once we have
experience with more patients. So how certain can you be that
you’ve improved survival? Maybe you’ve just improved selection.
I also would like to know your center’s philosophy on resection
of T4 and N3 disease. At operation no attempt was made to dissect
the N3 nodes. How do you know that you didn’t have N3 disease
left behind, even though the N2 nodes were sterilized?
Also, you had 7 T4 tumors, and none of these patients under-
went an extended resection. Four of the T4 tumors were inopera-
ble, and in the other 3 cases, as far as I can tell, there was no
extended resection. All these patients underwent simple lobectomy
or pneumonectomy. What is the philosophy of your surgical ap-
proach after induction chemoradiation? Does it not matter any-
more that the original site of disease be removed? Is it okay just to
remove the primary site of disease and the regional lymph nodes,
leaving N3 nodes that may contain residual tumor?
Finally, now that you’ve prognosticated, how are you going to
deal with the 60-year-old patient with squamous cell cancer? And
how are you going to deal with the identification of persistent N2
disease, which you presume is also N3 disease, in the patients with
initial N3 disease after the chemoradiation, since none of those
patients survived?
Dr DeCamp. I appreciate your insightful comments, Dr Gins-
berg, and certainly recognize your preeminence in this field.
Regarding your question as to our philosophy about single-
station versus multistation, intracapsular versus extracapsular, or
bulky disease, we did not discriminate nor did we stratify our
outcome analysis according to these factors. It is our philosophy
that mediastinal nodal involvement is a marker for systemic dis-
ease, and without an effective systemic form of treatment as part
of our treatment plan, we do not believe that we need to discrim-
inate between those. All of that being said, I’m a firm believer that
there are good IIIBs and bad IIIBs and good IIIAs and bad IIIAs;
however, we tend to enroll all patients with reasonable perfor-
mance status and any N2 or N3 involvement in this accelerated
schema.
It is true that this is a toxic regimen. All of the patients are
inpatients during the first week of both the induction and the
adjuvant portions of treatment for continuous infusion chemother-
apy and for adequate hydration to prevent renal toxicity. It’s also
Appendix TABLE 1. Pathologic response to accelerated
chemoradiotherapy in IIIA and IIIB tumors
Postresection tumor
classification
Stage IIIA
(n  78)
Stage IIIB
(n  27)
No. % No. %
ypT*
0 12 16 2 8
1 28 37 9 35
2 27 36 9 35
3 2 3 3 12
4 6 8 3 12
ypN†
0 24 32 8 32
1 5 7 1 4
2 45 61 3 12
3 0 0 13 52
*Unknown in 4 cases.
†Unknown in 6 cases.
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true that 40% of patients required unexpected readmission for
febrile neutropenia. There were no toxicity-related deaths before
induction therapy, and all 105 patients underwent surgery on time.
Seven patients could not be operated on, 6 because of progressive
disease and 1 because his forced expiratory volume in 1 second
was considered to limit resectability. The fact that this is toxic
therapy necessitates carefully coordinated care by the surgeon,
medical oncologists, and radiation oncologists, and we’re blessed
to have this expertise. Though we don’t have a cost-effectiveness
analysis, I think it would be an interesting comparison to look at
the total cost of this accelerated regimen versus the more standard
course.
I do take minor issue with your comment about our schema
being similar to SWOG 8805. In their Journal of Clinical Oncol-
ogy publication, the mean time to complete just the induction
portion of therapy in SWOG 8805 was 40 days. Ours was 12 days,
and there were no delays in getting our patients to surgery. In the
entire cohort of 105 patients, 74% completed all the prescribed
treatment in our schema. This was similar to the rate in SWOG
8805; however, only a fraction of their patients had any adjuvant
therapy prescribed.
Moving on to T4 and N3, we had 7 patients with T4 disease, 5
on the basis of direct mediastinal invasion and 2 because of
superior vena caval involvement. Both cases of superior vena caval
involvement were found to be unresectable at the time of explo-
ration, whereas most cases of mediastinal invasion were resect-
able. We did have one chest wall resection (T3). This is not a series
that could be easily compared with others with T4 lesions involv-
ing the esophagus, the aorta, or spine. We did not routinely make
an attempt to resect N3 disease at the time of our resection. We did
make the leap of faith assumption that sterilization of the N2 nodes
reflected sterilization of the N3 nodes. However, in our analysis we
assumed that if there was residual N2 disease in a patient who
originally had N3 disease that there was no downstaging. So the
downstaging reflected sterilization of the mediastinal nodes.
Other investigators, including Grunenwald, have advocated an
aggressive mode of resection, including sternotomy and bilateral
lymphadenectomy. I have a hard time reconciling that as providing
any therapeutic benefit. I do see that it would provide prognostic
information that would help us better understand what we’re doing
with induction chemoradiotherapy, but I think residual mediastinal
nodal disease is a marker that there is residual systemic disease.
In terms of the 60-year-old patient with squamous cell carci-
noma, obviously clinical judgment goes far beyond age and his-
tologic type. I would continue to advocate careful assessment
according to clinical judgment.
In terms of how we might go forward in terms of assessing
patients for residual nodal disease, I think the emerging technol-
ogies of computed tomography combined with positron-emission
tomography and a better understanding of the utility of positron-
emission tomography to assess response may help. Another con-
sideration would be the limited use of reoperative mediastinoscopy
or videothoracoscopy to evaluate patients for residual disease after
induction therapy. Resection may be futile for these patients, and
other novel therapies may be more appropriate.
Dr Thomas A. D’Amico (Durham, NC). Dr DeCamp, could
you share with us what you believe the role of radiation therapy in
induction protocols is? There is no evidence that it adds to long-
term survival. How would hyperfractionation then enhance that
role?
Second, what percentage of your patients had failure because of
brain metastasis, and can your study support the use of prophy-
lactic cranial irradiation in an induction therapy protocol?
Dr DeCamp. I think that if you look at pathologic response at
the time of surgery after induction, chemoradiation (SWOG 8805)
versus a straight chemotherapy induction regimen, for example,
the Cancer and Leukemia Group B (CALGB) 8935 study, you’ll
find that there were more overall responses, certainly more com-
plete responses and more downstaging, in the chemoradiation
trials. Those patients had more meaningful survival. So I do think
the use of radiotherapy with concurrent chemotherapy provides
treatment synergy, and it establishes that synergy early in the
course of therapy to enhance response and perhaps survival.
I don’t think we have the statistical power to support or refute
the use of prophylactic cranial irradiation. We had a less than 10%
local failure rate, whereas we had a 50% distant failure rate. Most
of those were in the brain. I think we have defined those people
who have responded and have potentially benefited from resection.
Because we can predict that nearly half are going to go on to have
brain metastasis, we would certainly support revisiting the use of
prophylactic cranial irradiation in this subset with pathologic re-
sponse and mediastinal sterilization.
Dr Douglas J. Mathisen (Boston, Mass). Our approach has
been similar to yours for IIIA nodal disease and fairly closely
mimics your experience. I have one simple question and one that
will take a little bit of explanation on your part. We noticed that
there were higher incidences of pulmonary embolism and adult
respiratory distress syndrome in both the treatment phase and the
postoperative phase, and I wonder whether you had any similar
experiences.
The more interesting question to me is about persistent nodal
disease. We have never taken the approach of doing remediasti-
noscopy and have accepted that there is some value in removing
local disease and doing nodal dissections and have had about a
20% survival rate in that group of patients with persistently pos-
itive nodal disease, and invariably somebody makes the comment
that the old CALGB study treating nodal disease with chemora-
diotherapy achieved roughly a 20% survival rate. My contention
has always been that in that group, their 20% survival rate was
likely to have been those who had a complete response to chemo-
radiotherapy. Would you address the issue of those who argue that
persistent disease ought to be treated with chemoradiotherapy and
use that CALGB study as justification. Obviously we don’t know,
but my suspicion has always been that it’s a different group of
patients.
Dr DeCamp. First, regarding the adult respiratory distress
syndrome issue, 4 or 5 of the 7 deaths were from respiratory
failure, adult respiratory distress syndrome, and multiple organ
failure. Interestingly, these were fairly evenly divided between
lobectomies and pneumonectomies. So it wasn’t just the fact that
a patient had undergone a pneumonectomy after chemoradiation.
We are acutely aware, even paranoid if you will, about that risk
and try to minimize the inspired oxygen fraction during the time of
resection. We also use a couple of doses of steroids. I know that’s
an anecdotally supported practice, and I don’t have any data to
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support it. It makes us feel a little better to try to preempt, if you
will, that difficult problem.
Regarding the role of surgery even with persistent nodal dis-
ease, I agree with you. The old CALGB nonsurgical trial had a
substantial local recurrence rate. We have substantially reduced
that local recurrence problem. We may be simply shifting the
natural history of the disease and demonstrating that with surgery
and radiation we provide exquisite local control. The Achilles heel
in the treatment schema for these patients is the lack of good,
effective systemic therapy. So I do think there is a role for
resection. I’m not sure that the role extends to N3 disease. I think
that patients who have residual N3 disease are truly nonresponders.
I’m not convinced that subjecting them to the morbidity of resection,
with or without bilateral lymphadenectomy, is in their best interest.
Dr Douglas E. Wood (Seattle, Wash). I don’t understand the
radiobiologic sense of a split course of radiation. I do under-
stand the chemotherapy before and the chemotherapy after, but
to me splitting the course of radiation seems to violate at least
what I know about the effectiveness of radiation. Can you
explain?
Dr DeCamp. You’re absolutely right. We had to take the
radiation oncologists out behind the barn and tie them up to get
them to agree to manage patients with a split course. It certainly
violates the fundamentals of radiobiology. I think it’s really a
compromise in terms of multimodality therapy. We wanted to
ensure that most patients got to surgery. We think most patients
who are cured of lung cancer are going to undergo resection. We
are concerned about the added toxicity of, for example, a second
cycle of induction therapy before resection. Our schema is clearly
a compromise from a radiation oncology standpoint, yet the results
are encouraging. Local control is excellent. We are continuing to
explore tweaking the schema in an effort to improve survival.
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